Boehringer cancelled agreement with Hanmi because of competing drug’s excellence
It was pointed out Boehringer Ingelheim decided to cancel the technology introduction agreement of ‘olmutinib’ with Hanmi Pharm because of its side effects and excellent results of other competing drugs.
Hyundai Securities indicated Boehringer Ingelheim suspended development of olmutinib because...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
